Pharmacokinetics of TDP223206 following intravenous and oral administration to intact rats and intravenous administration to bile duct-cannulated rats

Biopharmaceutics and Drug Disposition

Volumn 29, Issue 4, 2008, Pages 219-230

  Chen, Yanmin ^a   Cheng, Deping ^a   Marugan, Juan Jose ^b   Manthey, Carl ^a   Tomczuk, Bruce ^a   Huebert, Norman ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b Mithridion Inc   (United States)

Author keywords

v 3 receptor; Bile duct cannulated rats; Glucuronidation; Integrin; Pharmacokinetic

Indexed keywords

CARBON 14; GLUCURONIDE; PROTEIN INHIBITOR; TDP 223206; VITRONECTIN RECEPTOR INHIBITOR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BILE DUCT; BILE FLOW; CANNULATION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG TRANSFORMATION; ENTEROHEPATIC CIRCULATION; KIDNEY; LARGE INTESTINE; LIVER; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RADIOACTIVITY; RAT; SINGLE DRUG DOSE; SMALL INTESTINE; STEREOISOMERISM;

ADMINISTRATION, ORAL; ANIMALS; BILE; FECES; INDOLES; INJECTIONS, INTRAVENOUS; INTEGRIN ALPHAVBETA3; MALE; PROPIONIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 44949170828     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.601     Document Type: Article

References (19)

1. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992; 69: 11-25.
2. Humphries MJ. Integrin structure. Biochem Soc Trans 2000; 28: 311-339.
3. Eble JA. Integrin-Ligand Interaction. Springer-Verlag: Heidelberg, 1997; 1-40.
4. 3 integrin vitronectin receptor. Int J Biochem Cell Biol 1997; 29: 721-725
5. 3 integrin. J Bone Miner Res 1992; 7: 335-343.
6. 3 integrin with a small peptide antagonist GpenGRGDSPCA. J Vasc Surg 1994; 19: 125-134.
7. Liaw L, Almeida M, Hart CE, Schwartz SM, Giachelli CM. Osteopontin promotes vascular cell adhesion and spreading and is chemotactic for smooth muscle cells in vitro. Circ Res 1994; 74: 214-224.
8. v integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest 1999; 103: 1227-1230.
9. 3 integrin inhibits bone resorption in vitro and prevents osteoporosis in vivo. J Clin Invest 1997; 99 : 2284-2292.
10. Stupack DG, Storgard CM, Cheresh DA. A role for angiogenesis in rheumatoid arthritis. Braz J Med Biol Res 1999; 32: 573-581.
11. Strömblad S, Cheresh DA. Integrins, angiogenesis and vascular cell survival. Chem Biol 1996; 3: 881-885.
12. 3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res 1998; 58: 1930-1935.
13. Noiri E, Gailit J, Sheth D, et al. Cyclic RGD peptides ameliorate ischemic acute renal failure in rats. Kidney Int 1994; 46: 1050-1058.
14. 3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor. Blood 2000; 95: 368-374.
15. 5 in ocular neovascular diseases. Proc Natl Acad Sci USA 1996; 93: 9764-9769.
16. D'Souza SE, Ginsberg MH, Plow EF. Arginyl-glycyl-aspartic acid (RGD) - a cell-adhesion motif. Trans Biochem Sci 1991; 16: 246-250.
17. Keenan RM, Miller WH, Barton LS, et al. Orally bioavailable nonpeptide vitronectin receptor antagonists containing 2-aminopyridine arginine mimetics. Bioorg Med Chem Lett 1999; 9: 1801-1806.
18. 3 antagonists containing indol-1-ylpropionic acids. Bioorg Med Chem Lett 2005; 15: 2679-2684.
19. Davies B, Morris T. Physiological parameters in laboratory and humans. Pharm Res 1993; 10(N7): 1093-1095.